Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis

Annals of Hematology

Volumn 85, Issue 8, 2006, Pages 502-513

  Muller Berndorff H ^a   Haas, P S ^a   Kunzmann, R ^a   Schulte Monting J ^a   Lubbert M ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cytogenetics; Decitabine; Epigenetic therapy; Methylation; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CORTICOSTEROID DERIVATIVE; GROWTH FACTOR; MYELOABLATIVE AGENT;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER SURVIVAL; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DEATH; DISEASE CLASSIFICATION; DISEASE COURSE; ERYTHROCYTE APLASIA; FEMALE; FRANCE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; RETROSPECTIVE STUDY; SCORING SYSTEM; SPAIN; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANEMIA, SIDEROBLASTIC; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

EID: 33747821158     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0030-z     Document Type: Article

References (28)

1. Aul C, Bowen DT, Yoshida Y (1998) Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 83:71-86
2. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52-59
3. Aul C, Giagounidis A, Germing U, Ganser A (2002) Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 81:485-497
4. Aul C, Giagounidis A, Germing U, Ganser A (2002) Myelodysplastic syndromes. Diagnosis and therapeutic strategies. Med Klin 97:666-676
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
6. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood 89:2079-2088 (erratum, Blood, 91 1998:1100)
7. Haase D, Schanz J, Fonatsch C, Schoch C, Freund M, Haferlach T, WÖrmann B (1997) Correlation of karyotype with clinical features and prognosis in 349 patients with MDS. Leuk Res 21[Suppl. 1]:(Abstr. 50)
8. Harris NL, Jaffe ES, Diebold J, Flandrin G, Müller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
9. Heaney ML, Golde DW (1999) Myelodysplasia. N Engl J Med 340:1649-1660
10. Jaiyesimi IA, Friedline JA, Mattson JC, Gyorfi T (1999) Myelodysplastic syndrome at a large tertiary care community hospital: Analysis according to the international prognostic scoring system. Leuk Res 24:417-426
11. Lee JH, Shin YR, Lee YS, Kim WK, Chi HS, Park CJ, Seo EJ, Lee KH (2003) Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 17:305-313
12. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 114 2:349-357
13. Maes B, Meeus P, Michaux L, Bijnens L, Boogaerts M, Hagemeijer A, De Wolf-Peeters C, Verhoef G (1999) Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann Oncol 10:825-829
14. Mitelmann F (1995) An International System for Human Cytogenetic Nomenclature Karger, Basel, Switzerland
15. Mitelmann F (1991) Guidelines for cancer cytogenetics; supplement to "An international system for human cytogenetic nomenclature"; recommendations of the Standing Committee on Human Cytogenetic Nomenclature. Cancer Cytogenetics
16. Morel P HM, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromesand can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315-1323
17. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 59:425-433
18. Pfeilstöcker M, Reisner R, Nösslinger T, Gruner H, Nowotny H, Tuchler H, Schlogl E, Pittermann E, Heinz R (1999) Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 106:455-463
19. Pitako JA, Haas PS, van den Bosch J, Müller-Berndorff H, Kündgen A, Germing U, Wijermans PW, Lübbert M (2005) Qualification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndromes treated with low-dose decitabine: A matched-pair analysis. Ann Hematol 84(Suppl 1):25-31
20. Sanz GF, Sanz MA, Greenberg PL (1998) Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 83:358-368
21. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395-408
22. Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E, Prieto F, Granada I, Hernandez JM, Cigudosa JC, Diez JL, Bureo E, Marques ML, Arranz E, Rios R, Martinez Climent JA, Vallespi T, Florensa L, Woessner S (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108:346-356
23. Sperr WR, Wimazal F, Kundi M, Fonatsch C, Thalhammer-Scherrer R, Schernthaner GH, Schwarzinger I, Haas OA, Geissler K, Lechner K, Valent P (2001) Survival analysis and AML development in patients with de novo myelodysplastic syndromes: Comparison of six different prognostic scoring systems. Ann Hematol 80:272-277
24. Wijermans P, Lübbert M, Verhoef G, Klimek V, Bosly A, Ferrant A. An epigenetic approach for the treatment of advanced MDS; the experience with DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine). Ann Hematol 84(Suppl 1):9-17
25. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962
26. Wimazal F, Sperr WR, Kundi M, Meidlinger P, Fonatsch C, Jordan JH, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Lechner K, Valent P (2001) Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res 25:287-294
27. Yunis JJ, Rydell RE, Oken MM, Arnesen MA, Mayer MG (1986) Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood 67:1721-1730
28. Zhao WL Xu L, Wu W (2002) The myelodysplastic syndromes: Analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution. Hematol J 3:137-144